The Novavax shot has shown good results in trials in children aged three and older, said Adar Poonawalla
New Delhi: The Serum Institute of India (SII) plans to launch the Novavax (NVAX.O) COVID-19 vaccine for children in the country in six months, its CEO said on Tuesday, adding global vaccine supplies were outstripping the absorption capacity of many countries.
The Novavaxshot, which the world's largest producer of vaccines calls Covovax, has shown good results in trials in children aged three and older, Adar Poonawalla told a virtual conference organised by the Confederation of Indian Industry.
"Our vaccine will be launched in six months," he said. "It is under trial and has shown excellent data all the way down to the age group of 3."
Apart from the Novavax vaccine that it has already exported to countries such as Indonesia, SII also makes the AstraZeneca (AZN.L) and Sputnik shots.
SII's monthly output of the AstraZeneca vaccine has nearly quadrupled since April to 250 million doses, and it has announced plans to temporarily halve that production due to weak demand. read more
Poonawalla said current global vaccine supply was far bigger than what many countries could consume despite them inoculating only a fraction of their population, mainly due to infrastructure shortages. read more
"Globally, including in India, the supply has outmatched the demand," he said. "Certain countries have only vaccinated to the tune of 10% or 15% of the population, they really need to go to 60-70%."